Vaccine Drought Spurs NIAID Plan to Improve Industry

摘要

WASHINGTON, D.C—The world's premier annual AIDS vaccine meeting used to have an entire session devoted to the results of initial human tests of candidate vaccines. But not this year. Organizers of the 8th Annual Conference on Advances in AIDS VaccineDevelopment, put on by the National Institute of Allergy and Infectious Diseases (NIAID), deemed that only one early vaccine strategy had produced clinical results sufficiently promising to merit an oral presentation. "There's not a great deal out there, and that's a concern," says Patricia Fast, who heads NIAID's AIDS vaccine division. Dani Bolognesi, an AIDS vaccine researcher at Duke University, is similarly worried. "The pipeline [of new AIDS vaccines] is almost shut down," says Bolognesi.